Selective laser trabeculoplasty for glaucoma in sub-Saharan Africa - Author's reply

Heiko Philippin¹, David Macleod², Einoti Matayan³, Gus Gazzard⁴, Peter Shah⁵, William U Makupa³, Matthew J Burton⁶

Affiliations

¹ International Centre for Eye Health, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Eye Department, Kilimanjaro Christian Medical Centre, Moshi, Tanzania; Eye Centre, Medical Centre-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Electronic address: heiko.philippin@lshtm.ac.uk.
² MRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.
³ Eye Department, Kilimanjaro Christian Medical Centre, Moshi, Tanzania; Kilimanjaro Christian Medical University College, Moshi, Tanzania.
⁴ NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust-University College London Institute of Ophthalmology, London, UK; University College London Institute of Ophthalmology, London, UK.
⁵ University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; University College London Institute of Ophthalmology, London, UK; Birmingham Institute for Glaucoma Research, Institute of Translational Medicine, University Hospitals Birmingham, Birmingham, UK; Centre for Health and Social Care Improvement, University of Wolverhampton, Wolverhampton, UK.
⁶ International Centre for Eye Health, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust-University College London Institute of Ophthalmology, London, UK.

PMID: 35180415
DOI: 10.1016/S2214-109X(21)00589-1

Free article

Comment

Selective laser trabeculoplasty for glaucoma in sub-Saharan Africa - Author's reply

Heiko Philippin et al. Lancet Glob Health. 2022 Mar.

Free article

. 2022 Mar;10(3):e335.

doi: 10.1016/S2214-109X(21)00589-1.

Authors

Heiko Philippin¹, David Macleod², Einoti Matayan³, Gus Gazzard⁴, Peter Shah⁵, William U Makupa³, Matthew J Burton⁶

Affiliations

¹ International Centre for Eye Health, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Eye Department, Kilimanjaro Christian Medical Centre, Moshi, Tanzania; Eye Centre, Medical Centre-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Electronic address: heiko.philippin@lshtm.ac.uk.
² MRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.
³ Eye Department, Kilimanjaro Christian Medical Centre, Moshi, Tanzania; Kilimanjaro Christian Medical University College, Moshi, Tanzania.
⁴ NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust-University College London Institute of Ophthalmology, London, UK; University College London Institute of Ophthalmology, London, UK.
⁵ University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; University College London Institute of Ophthalmology, London, UK; Birmingham Institute for Glaucoma Research, Institute of Translational Medicine, University Hospitals Birmingham, Birmingham, UK; Centre for Health and Social Care Improvement, University of Wolverhampton, Wolverhampton, UK.
⁶ International Centre for Eye Health, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust-University College London Institute of Ophthalmology, London, UK.

PMID: 35180415
DOI: 10.1016/S2214-109X(21)00589-1

No abstract available

PubMed Disclaimer

Conflict of interest statement

GG reports personal fees from Alcon, Allergan, Belkin, Equinox, Genentech–Roche, Glaukos, Ivantis, Reichert, Sight Sciences, and from Thea; grants from Belkin, Santen, and from Thea; and non-financial involvement with the patient advocacy group GlaucomaUK, outside the submitted work; he is also a co-investigator on three other major SLT trials (LiGHT, COAST, and Belkin laser). All other authors declare no competing interests.

Comment in

Selective laser trabeculoplasty for glaucoma in sub-Saharan Africa.
Fu MX. Fu MX. Lancet Glob Health. 2022 Mar;10(3):e334. doi: 10.1016/S2214-109X(21)00591-X. Lancet Glob Health. 2022. PMID: 35180414 No abstract available.

Comment on

Selective laser trabeculoplasty versus 0·5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial.
Philippin H, Matayan E, Knoll KM, Macha E, Mbishi S, Makupa A, Matsinhe C, da Gama V, Monjane M, Ncheda AJ, Mulobuana FA, Muna E, Fopoussi N, Gazzard G, Marques AP, Shah P, Macleod D, Makupa WU, Burton MJ. Philippin H, et al. Lancet Glob Health. 2021 Nov;9(11):e1589-e1599. doi: 10.1016/S2214-109X(21)00348-X. Epub 2021 Oct 13. Lancet Glob Health. 2021. PMID: 34655547 Free PMC article. Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

MR/R010161/1/MRC_/Medical Research Council/United Kingdom

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Selective laser trabeculoplasty for glaucoma in sub-Saharan Africa - Author's reply

Affiliations

Selective laser trabeculoplasty for glaucoma in sub-Saharan Africa - Author's reply

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical